Diagnostics to support the scaling up of shorter, safer tuberculosis regimens.

Autor: Branigan D; Treatment Action Group, New York, NY 10004, USA. Electronic address: david.branigan@treatmentactiongroup.org., Denkinger CM; Division of Infectious Disease and Tropical Medicine, Heidelberg University Hospital, Heidelberg, Germany; German Centre for Infection Research (partner site), Heidelberg, Germany., Furin J; Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA., Heitkamp P; TBPPM Learning Network, McGill University, Montreal, QC, Canada., Deborggraeve S; Médecins Sans Frontières Access Campaign, Geneva, Switzerland., van Gemert W; Stop TB Partnership, Geneva, Switzerland., Herrera R; Global Tuberculosis Community Advisory Board, Mexicali, México., Kondratyuk S; International Treatment Preparedness Coalition, Kyiv, Ukraine., McKenna L; Treatment Action Group, New York, NY 10004, USA., Ndjeka N; National TB Programme, Pretoria, South Africa., Omar SV; Centre for Tuberculosis, National Institute for Communicable Diseases a division of the National Health Laboratory Service, Johannesburg, South Africa., Pai M; McGill International TB Centre, McGill University, Montreal, QC, Canada.
Jazyk: angličtina
Zdroj: The Lancet. Microbe [Lancet Microbe] 2023 Oct; Vol. 4 (10), pp. e758-e760. Date of Electronic Publication: 2023 Jul 31.
DOI: 10.1016/S2666-5247(23)00217-3
Abstrakt: Competing Interests: We declare no competing interests.
Databáze: MEDLINE